

## Saskatchewan Immunization Manual Amendments **May 2019**

**Instructions:** Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **May 2019**

### **Chapter 3 – Informed Consent**

- P. 5 – Step by Step Process for Obtaining Informed Consent – Adults
  - Substitute decision maker (SDM) added to first 2 bullets.
  - 3<sup>rd</sup> bullet removed as SDM addresses issue.
- P. 16 Appendix 3.2 Relative Risk of Vaccine-Preventable Diseases and Immunizations
  - New! Hepatitis A added to table.
  - HPV updated as per CIG

### **Chapter 4 – Documentation**

- TOC – Appendix 4.2 added to page
- New! *Where do I document?* (Bulletin 24) incorporated into this chapter as Appendix 4.2.
  - Scenarios are numbered, pages are not numbered.
  - Content changes
    - #6 amended
    - #14 is new
    - #18 amended
    - #36 amended
    - #37 amended
    - #50 amended
    - #62 is new
    - #63 is new
    - #69 is new

### **Chapter 5 – Immunization Schedules**

- P. 11 – Min. Intervals for Specific Vaccine Series
  - All meningococcal conjugate vaccines (except for Menactra®) used in Saskatchewan now have 6 weeks old as the minimum age to avoid delay or disruption to routine or risk factor indication schedules.
  - Duplicate HA removed.
  - Age 4 years is min. age for IPV series.
  - HPV 3-dose series has no age parameters.
- P. 28 – Appendix 5.2
  - New! Countries that children and adults do not require MMR vaccine if travelling to are listed.

### **Chapter 6 – Contraindications and Precautions**

- P. 1 Section 1.3 Client Assessment –
  - 2<sup>nd</sup> sentence now states: Consult a Medical Health Officer (MHO) for recommendations as appropriate.

### **Chapter 7 – Special Populations**

- P. 27 – Section 6.3 Publicly Funded Vaccines Health Care Worker – Eligible for Publicly Funded Vaccines
  - Example given to reinforce that 10 years requirement between tetanus-diphtheria vaccines is recommended:
    - *For example, a nursing student who received Tdap at age 14 is eligible to receive Tdap at age 24 years and is not recommended to receive it sooner regardless of employer or educational institution.*

## Saskatchewan Immunization Manual Amendments **May 2019**

- P. 39 Appendix 7.4
  - **New!** Note added under heading that states: \*NOTE: If any dose in a series for those 16 and older is **ENGERIX®-B, a 4-dose series** must be given.
- P. 43 Appendix 7.8
  - All varicella columns now state: Refer to [Appendix 5.4 Publicly Funded Varicella Immunization Eligibility](#).
  - HC – bullets removed, now states refer to footnote 2.

### **Chapter 8 – Administration of Biological Products**

- TOC 2<sup>nd</sup> page – **Appendix 8.4 added.**
- P. 21 – Section 2.1 Oral (PO)
  - Reference made to **Appendix 8.4 – Oral Vaccine Administration via Enteral Tubes**
- P. 35 **NEW!** **Appendix 8.4 – Oral Vaccine Administration via Enteral Tubes**
  - This is a standard work documents. Please review with staff.

### **Chapter 10 Biological Products**

- Hepatitis B Vaccine - Immigrant Populations Ineligibility List
  - **Adult references removed from document.**
- Hepatitis B Series Completion Recommendations for Children Presenting at 11-15 Years Old
  - **New scenario # 13 added, please review.**
- HPV-9 (first page)
  - Sentence added to last bullet Indications: (**series must start before 27th birthday for remaining doses to be publicly funded**).
- Menjugate Liquid, Neis-Vac-C, and Menveo **all minimum ages are 6 weeks old.**
- Bexsero
  - **Dose/series section updated as per 2019 product monograph.**
- Prevnar 13 Page 2 of 2
  - (**including adults**) **added to** solid organ or islet cell transplant recipient and candidate, and to HSCT recipient.
- Imovax Rabies –
  - **New product monograph. Swollen lymph nodes added to expected reactions.**
- Tubersol
  - **TB skin test result interpretations have been removed and the following is noted: Refer to *Canadian Tuberculosis Standards* (7th Ed.) Available at: <http://www.respiratoryguidelines.ca/tb-standards-2013>.**
- **HYPERRAB® S/D**
  - Is **currently available** as a 1 mL 300 IU vial **and** as a 2 mL 300 IU vial (150 IU/mL) so **always review vial label for concentration when calculating dosage.**

### **Chapter 14 Appendices**

- **2019-20 influenza start date letter**